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ABSTRACT
Background. Few data are available on allograft survival at 15
years, the impact and the predictors of recurrence of the
original disease in renal transplanted patients with IgA ne-
phropathy (IgAN).
Methods. In this retrospective study, we compared the long-
term outcome of renal transplant in 190 patients with IgAN
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with that of 380 non-diabetic controls and evaluated the
impact of recurrence of IgAN on the graft outcome.
Results. At 15 years, the patient survival was 88.3% in IgAN
patients and 82.6% in controls (P = 0.12), while the death-cen-
sored graft survival was 62.6 and 72.4%, respectively
(P = 0.038). IgAN had a higher cumulative incidence of graft
failures in comparison with controls even considering death as
a competing risk (P = 0.025). At multivariate analysis, IgAN
[relative risk (RR) = 1.468, P = 0.026], delayed graft function
recovery (RR = 2.394, P = 0.000) and acute rejection
(RR = 2.51, P = 0.000) were predictive of graft loss. IgAN re-
curred in 42 grafts (22.1%), of them, 12 were lost for recur-
rence and in another 6 recurrence was considered a
concomitant cause of graft loss. The 15-year death censored
graft survival was 68.3% in non-recurrent and 51.2% in recur-
rent patients (P = 0.069). Pure graft survival of non-recurrent
IgAN patients was similar to that of controls (P = 0.406). At
Cox analysis, the recurrence of IgAN signiﬁcantly reduced
from 1981 to 2010 (P = 0.0065, RR = 0.936).
Conclusions. IgAN emerged as an independent predictor of
worse graft outcome in the long-term. Recurrence of IgAN
seems to progressively reduce in transplants performed from
1981 to 2010.
INTRODUCTION
IgA nephropathy (IgAN) is the most common primary glo-
merulonephritis worldwide [1], and causes end-stage renal
disease in 20–40% of patients at around 20 years after its diag-
nosis [2]. Kidney transplant is the treatment of choice for
patients with end-stage renal disease secondary to glomerulo-
nephritis. The available comparisons between the graft survi-
val of IgAN patients and that of a control group underline that
during the ﬁrst 5 years after transplantation, allograft survival
for primary IgAN patients is better than that of patients with
other primary diseases [3–5], at 10 years, graft survival of
IgAN patients becomes comparable with that of other diseases
[3, 6] or is even worse after 12 years [7]. Few data are available
on the outcome of IgAN-transplanted patients after 10 years
[7, 8]. Ponticelli and Glassock [9] suggest that with the pro-
longation of the follow-up, the recurrence of IgAN may
become a substantial risk factor for graft failure. As a matter of
fact, the possibility of recurrence of the original glomerulone-
phritis in the allograft is a well-established complication [10].
Recurrence is a time-dependent event, whose prevalence in-
creases as the duration of follow-up grows, and it is reported
to be the third cause of graft loss 10 years after kidney trans-
plantation [11]. In IgAN patients, routine graft biopsies [12]
demonstrated a histological recurrence in 53% of cases
although some patients had no clinical manifestations. The re-
currence rate of patients receiving graft biopsies for clinical
indication only ranged from 13 to 50% [3, 4, 6, 7, 13–24].
This wide range in the rate of recurrence can be attributed to
the different policy of graft biopsy of the different centres and
to the differing durations of follow-ups of the published
studies. Graft loss from recurrence was reported to be between
1.3 and 16% [3, 4, 6, 7, 12–23]. The aims of this single-centre
retrospective analysis were (i) to compare the long-term
patient and renal allograft survival of IgAN patients with those
of a well-matched control group and (ii) to evaluate the rate,
outcome and predictors of recurrence in renal transplant reci-
pients with IgAN.
SUBJECTS AND METHODS
Patients
One hundred and ninety patients with end-stage renal
disease due to biopsy-proven primary IgAN received a renal
transplantation in our unit between 1981 and 2010. Thirteen
of these patients lost the graft and received, in the same period,
a second renal transplant. In six of these patients, the ﬁrst graft
was lost for recurrence 33–224 months after transplant. Recur-
rence developed in only one of the second grafts and this graft
was lost for recurrence again 152 months after transplant.
Some of these patients are included in a previously published
paper [6].
Thirty-six ﬁrst transplantations were from living-related
donors (18.9%) and 154 were from deceased donors.
Patients receiving a renal transplant in the same period
(+/−3 months before or after), matched for age (+/−5 years),
gender and source of the donor were chosen as controls. Of
380 controls, 76 patients were carriers of autosomal dominant
polycystic kidney disease, 72 had hypertensive nephrosclerosis,
61 chronic pyelonephritis, 59 urological malformations/path-
ologies, 24 Alport syndrome, 43 interstitial nephritis, 6 ne-
phronophthisis, 31 systemic diseases and 8 other causes. None
of the controls had diabetes as original disease.
Deﬁnitions
Biopsy policy. Whenever an acute episode of renal
dysfunction of doubtful origin, persistent proteinuria >0.5 g/
day or persistent microscopic haematuria of non-urological
origin developed, the patient was subjected to graft biopsy. In
addition, all patients with progressive renal dysfunction re-
ceived one more more graft biopsy.
Evaluation of renal biopsies. All biopsies were evaluated by
light microscopy and by immunoﬂuorescence. Electron
microscopy was performed in about one-third of cases.
Diagnosis of recurrence of IgA. Diagnosis of recurrence of
IgA was performed by immunoﬂuorescence positive staining
for IgA in the mesangial area. Recurrent biopsies were evalu-
ated according to the Oxford classiﬁcation [25].
Deﬁnition of graft loss causes. Graft loss was attributed to
recurrent IgAN when renal histology showed diffuse mesan-
gial proliferation and/or segmental necrosis of the tuft associ-
ated with extracapillary proliferation and glomerular sclerosis.
These lesions were usually associated with progressive worsen-
ing of proteinuria and severe haematuria. When interstitial
inﬂammation and transplant arteriopathy were observed, the
failure of the graft was attributed to chronic active T-cell-
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mediated rejection. The presence of peritubular capillary
deposition of C4d associated with the positivity of anti-HLA
antibodies in the serum of patients suggested the diagnosis of
chronic active antibody-mediated rejection. In some cases, the
failing graft showed only interstitial ﬁbrosis and tubular
atrophy.
When the previously described glomerular and vascular
lesions were coexisting, the graft loss was attributed to a
mixture of IgAN and rejection.
Delayed graft function recovery. Delayed graft function re-
covery was deﬁned by a slow decrease in serum creatinine,
either requiring dialysis or not and persisting for at least 2
weeks.
Acute rejection. Acute rejection was diagnosed on the basis
of a double-checked increase of ≥30% of plasma creatinine
over the baseline, not explained by other causes.
The severity of rejection and the classiﬁcation of chronic
lesions were scored retrospectively according to the recently
revised Banff classiﬁcation [26].
Immunosuppression
The immunosuppressive therapy of IgAN patients and of
controls is reported in Table 1. Acute T-cell-mediated rejec-
tions were treated with intravenous methylprednisolone pulse
therapy, and antibodies-mediated rejections with anti-thymo-
cyte globulins.
Statistical analysis
The statistical package S-Plus was used to analyse sample
data. Since most of the variables showed non-normal distri-
bution, the median and interquartile ranges were used for de-
scriptive analysis. As well, the non-parametric Wilcoxon test
was used to evaluate the differences between the two groups of
patients. Cross-tabulated data were analysed by the Chi-square
test or by the Fisher test when the expected cell count was less
than ﬁve. Patient survival, graft survival and recurrence-free
survival curves were drawn using the Kaplan–Meier estimate
and compared using the log-rank test. Univariate Cox pro-
portional hazards models were used to investigate the signiﬁ-
cance of each prognostic factor for graft loss and for
recurrence. All factors reported in Table 1 were tested as pre-
dictors of graft loss, and those reported in Table 2 were tested
as predictors of recurrence. In addition, the year of transplant
was tested as predictor or recurrence. Statistically signiﬁcant
factors were then tested in multivariate analysis. Only acute re-
jections occurring within the ﬁrst post-transplant year were
considered for analysis as non-time-dependent variables. Rela-
tive risk (RR) for each covariate was derived from the Cox
model as the antilogarithm of its estimated coefﬁcient, and
95% conﬁdence interval (CI) was computed as the antiloga-
rithm of coefﬁcient ± 1.96 × standard error of the coefﬁcient.
Competing risk analyses were performed with NCSS software
considering the cumulative incidence of graft failure and
death. The signiﬁcance of differences between cumulative inci-
dence curves was estimated by the Gray test [27].
RESULTS
The median values with interquartile ranges of demographic
and clinical characteristics of IgAN patients and of controls are
reported in Table 1. The only signiﬁcant differences between
the two groups were a signiﬁcantly longer duration of dialysis
in controls (P = 0.014) and a higher number of hypertensive
patients in the IgAN group (P = 0.0017).
Patient and graft survival
The median post-transplant follow-up was 113.1months
(60.5–165.1) for IgAN patients and 115 months (59.2–174.2)
for controls (P = ns).
The actuarial 15-year patient survival rates were 88.3% in
IgAN patients and 82.6% in controls (P = 0.12) (Figure 1A).
Fourteen patients in the IgAN group died (7.36%) after a
median follow-up of 73.2 months (32.6–111.8). In the control
group, 50 patients died (13.2%) after a median follow-up of
109.2 months (48.9–172).
Fifty-eight out of 190 grafts (30.5%) in IgAN patients were
lost at 98.4 months (44.6–132.9) after transplantation. In the
control group, 87 graft failures (22.8%) occurred at 115.3
months (64.4–171.3) after transplantation.
The actuarial death-censored graft survival rates at 15 years
were 62.6% in IgAN patients and 72.4% in the control group
(P = 0.038) (Figure 1B). The cumulative incidence of graft
failure of IgAN patients conﬁrmed to be higher (86%) than
that of controls (39%) even considering death as a competing
risk (P = 0.025).
The variables reported in Table 1 were tested as predictors of
graft loss for the whole population in the study. At univariate
analysis, delayed graft function recovery (P = 0.000, RR = 2.57,
CI 1.81–3.67), the occurrence of acute rejection within the ﬁrst
year after transplant (P = 0.000, RR = 2.72, CI 1.95–3.78), less
than three immunosuppressive drugs (P = 0.013, RR = 0.665, CI
0.47–0.91) and IgAN in the original kidneys (P = 0.039,
RR = 1.42, CI 1.01–1.98) were predictors of graft loss. At multi-
variate analysis, IgAN (P = 0.026, RR = 1.468, CI 1.0459–
2.0607), delayed graft function recovery (P = 0.000, RR = 2.394,
CI 1.6725–3.4269) and acute rejection (P = 0.000, RR = 2.51, CI
1.79–3.5) were independent predictors of graft loss.
In IgAN patients transplanted from deceased donors,
patient and death-censored graft survivals at 10 years were 93
and 73.8%, respectively, similar to the 89 and 85.2% observed
in those transplanted from living-related donors. (P = ns, both
for patient and graft survival).
Outcome of transplant patients with IgAN in their native
kidneys
During a median follow-up of 113.1 months, 113 patients
with IgAN (59.5%) were subjected to graft biopsy (46 patients
received two or more renal biopsies). Recurrence of IgAN was
documented in 42 patients accounting for 22.1% of the total
number of IgAN-transplanted patients and for 37.2% of
patients subjected to graft biopsy. Recurrence developed in 11
out of the 36 grafts (30%) from living-related donors and in 31
out of 154 grafts from deceased donors (20.12% P = ns). The
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Table 1. Demographic, clinical and laboratory characteristics and outcome of renal transplant
recipients with IgAN and controls
IgAN (N = 190) Controls
(N = 380)
P*
Age (years) at transplant, N (%) 42.5 (33.6–51.4) 42.3 (32.9–51.4) 0.92
Sex (male/female) 149/41 298/82 0.96
Living/deceased donors, N 36/154 72/308 0.91
Duration of dialysis, months 30.2 (14.2–52.8) 38.3 (19.5–61.6) 0.014
Type of dialysis HD/CAPD/pre-emptive 162/27/1 322/58 0.85
HLA match N 3 (2–3) 3 (2–3) 0.84
Panel-reactive antibodies %
Mean ± standard deviation 4.65 ± 13.9 5.22 ± 14.6 0.65
Cold ischaemia (hours) 14.4 (11.8–18.4) 15.3 (11.5–19.2) 0.33
Delayed graft function recovery, N (%) 27 (14%) 77 (20%) 0.08
P + azathioprine, N 5 12 0.93
P + cyclosporine, N 44 104 0.32
Cyclopsorine, N 7 5 0.32
P + cyclosporine + azathioprine, N 36 79 0.68
P + cyclosporine + mycophenolate, N (%) 31 54 0.58
P + tacrolimus + azathioprine, N 1 2 0.55
P + tacrolimus + mycophenolate, N 43 93 0.70
m TOR inhibitors + cyclosporine, N 1 1 0.80
P + tacrolimus N 3 5 0.90
P +m TOR inhibitors + cyclosporine N 15 17 0.12
P +m TOR inhibitors + mycophenolate, N 4 8 0.75
Induction with anti-CD25 antibodies
Basiliximab, N (%) 53 (27.8) 96 (25.3) 0.52
Mycophenolate, N (%) 78 (41) 155 (40.7) 0.99
Tacrolimus, N (%) 47 (24.7) 100 (26.3) 0.66
m TOR inhibitors, N (%) 20 (10.5) 26 (6.8) 0.13
Triple immunosuppression, N (%) 130 (68.4) 245 (64.4) 0.39
Acute rejections within the ﬁrst year
N (%) 77 (40.5) 125 (32.8) 0.08
Arterial hypertension, N(%) 177 (93.1) 315 (82.9) 0.0017
Follow-up post-transplant, months 113.1 (60.5–
165.1)
115 (59.2–174.2) 0.42
Grafts lost for recurrence, N (%) 12 (6.3)
Grafts lost for chronic active T-cell-mediated rejection, N
(%)
21 (11)a 34 (8.9) 0.51
Grafts lost for chronic active antibody-mediated rejection, N
(%)
6 (3.15)b 13 (3.4) 0.93
Continued
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clinical presentation of recurrences developed in median 44.8
(21.6–78.9) months after transplantation with isolated micro-
scopic haematuria in 5, isolated proteinuria in 8, microscopic
haematuria and proteinuria in 12, increase in plasma creati-
nine in 17: isolated in 4, associated with haematuria or haema-
turia and proteinuria in the other cases. Proteinuria and
haematuria developed during the subsequent follow-up in the
four patients with isolated increase in serum creatinine at renal
biopsy, instead in seven patients all the urinary abnormalities
regressed during a median follow-up of 203 months.
A renal biopsy was performed 4.9 months (range 1.64–22.2
months) after the clinical presentation of the recurrence. The
Oxford classiﬁcation [25] of the histological lesions of recur-
rent grafts is reported in Table 3.
The outcome of IgAGN patients is reported in the Gantt
chart (Figure 2).
Twenty-two out of 42 recurrent grafts (52.4%) were lost
within 176.8 months (86.1–166.5). Twelve graft losses were at-
tributed to recurrence (54.5%), and in another six grafts, re-
currence was considered a concomitant cause of graft loss.
Altogether, 52.4% of recurrent grafts were lost at 176.8 months
(86.1–166.5) after transplant in comparison to 24.3% of non-
recurrent grafts lost at 62 months (19.7–110.3) after trans-
plant.
The death censored graft survival at 15 years was 51.2 in re-
current patients versus 68.3 in non-recurrent patients
(P = 0.069) (Figure 3A). Graft survival in non-recurrent
patients was not signiﬁcantly different from that of controls
(P = 0.406) (Figure 3B).
Crescents in at least 30% of glomeruli were documented in
9 out of the 43 biopsies of recurrent grafts (including the re-
currence in one of the second transplants): of them 8 lost the
graft (88.8%) versus 13 graft losses out of 34 recurrences
without crescents at renal biopsy (38.2%, P = 0.02).
Predictors of recurrence
At Cox analysis, the recurrence of IgAN signiﬁcantly
reduced from 1981 to 2010 (P = 0.0065, RR = 0.936, CI
0.8921–0.9816). For descriptive purposes, the Kaplan–Meier
curves were drawn referring to three decades (1981–1989, 32
patients; 1990–1999, 97 patients; 2000–2010, 74 patients). As
shown in Figure 4, the log-rank test shows a signiﬁcant differ-
ence between the three curves (P = 0.018) (Table 2).
At univariate analysis, in addition to the year of transplant,
younger age (P = 0.0054), treatment without mycophenolate
(P = 0.016) and less than three immunosuppressive drugs
(P = 0.006) were predictive of recurrence. We found signiﬁcant
correlations of the above-mentioned variables among them. In
detail, the year of transplant showed a direct correlation with
the age of patients at transplant (Pearson correlation
coefﬁcient = 0.39, P < 0.000), with mycophenolate (Spearman
rho = 0.72, P < 0.0001) and with triple immunosuppressive
therapy (Spearman rho = 0.56, P < 0.0001). Due to these sig-
niﬁcant correlations, the only independent variables at
multivariate analysis were age at transplant (P = 0.038,
RR = 0.971 for each year CI 0.9451–0.9984) and triple immu-
nosuppressive therapy (P = 0.055, RR = 0.529 for each year, CI
0.42346–1.54998).
Treatment of recurrences
Twenty-six out of 42 recurrent patients (69%) were treated
with angiotensin-converting inhibitors alone, and 15 of them
lost the graft (57.6%). Eight patients with declining graft func-
tion were treated with three intravenous methylprednisolone
pulses (associated with angiotensin-converting inhibitors in
two patients), ﬁve of these grafts were lost (62.5%). The other
eight patients continued with the basal immunosuppressive
therapy, two of them lost the graft.
DISCUSSION
In this paper, we have reported the ﬁndings of a single-center
concerning renal transplantation in patients with IgAN. One
hundred and ninety patients were included in the study and
their outcome has been compared with that of an age- and
sex-matched control group including 380 patients. The only
signiﬁcant differences between the two groups were a longer
duration of dialysis in control patients and a higher number of
hypertensive patients in the IgAN group. IgAN patients and
controls have been followed for up to 10 years after renal
transplantation, one of the longest follow-ups reported until
Table 1. Continued
IgAN (N = 190) Controls (N = 380) P*
Grafts lost for interstitial ﬁbrosis and tubular atrophy, N (%) 10 (5.3) 13 (3.4) 0.4
Grafts lost for other causes, N (%) 9 (4.7) 27 (7.1) 0.36
Total grafts lost, N (%) 58 (30.5) 87 (22.8) 0.038
IgAN, IgA nephropathy; P, prednisone; CAPD, continuous ambulatory peritoneal dialysis; HD, haemodialysis. All the values are reported
as median and interquartile ranges if not differently speciﬁed.
*P-value refers to the statistical signiﬁcance of the variables either in the Cox proportional hazard regression (for a continuous variable) or
in the log-rank test for survival curve differences (for a discrete or discretized variable).
aRecurrence was considered as a concomitant cause of graft loss in two cases of chronic/active T-cell-mediated rejection.
bRecurrence was considered as a concomitant cause of graft loss in four cases of chronic active antibody-mediated rejection.
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now to the best of our knowledge. The length of the obser-
vation is important in the evaluation of the graft outcome in
IgAN patients. As a matter of fact in published studies, the
graft survival of IgAN patients seems to worsen in the long-
term in comparison to that of controls. In the ﬁrst 5 years after
transplantation, graft survival in IgAN patients was reported
Table 2. Demographic, clinical and laboratory characteristics and outcome of patients with IgAN
who recurred and those who did not
Recurrent grafts 42 Non-recurrent grafts:
148
P*
Age at tx (years) 37.4 (26.1–43.1) 44.1 (35.3–51.8) 0.0054
Sex of the recipient (male/female) 34/8 115/33 0.93
Duration of dialysis (months) 19.37 (10.6–40.4) 34.8 (16.9–54.6) 0.23
Type of dialysis HD/CAPD/pre-emptive 39/3 123/24/1 0.38
Deceased/living donors 31/11 123/25 0.11
HLA match, N 3 (2–3) 3 (2–3) 0.11
Panel-reactive antibodies %
Mean ± standard deviation 4.07 ± 12.17 4.78 ± 14.4 0.81
Cold ischaemia (hours) 13.4 (10–19.2) 15 (12.2–18.32) 0.37
Delayed graft function recovery
N (%) 5 (12.2) 22 (15.1) 0.89
Induction with anti-CD25 antibodies [basiliximab, N
(%)]
4 (9.5) 49 (33.1) 0.06
Mycophenolate therapy, N (%) 8 (19) 70 (47.3) 0.016
Triple immunosuppression, N (%) 21 (50%) 109 (73.6) 0.006
Tacrolimus, N (%) 4 (9.5) 43 (29.5) 0.1
m TOR inhibitors therapy, N (%) 5 (11.9) 15 (10.1) 0.66
Arterial hypertension, N (%) 41 (97.6) 136 (91.9) 0.49
Acute rejection, N (%) 22 (52.3) 55 (37.2) 0.11
Follow-up post-tx (months) 132.7 (77.4–176.8) 100.7 (55.7–157.0) 0.01
Grafts lost for recurrence, N (%) 12 (28.5) 0
Grafts lost for chronic active T-cell-mediated rejection, N
(%)
3 (7.1)a 18 (12.2) 0.52
Grafts lost for chronic active antibody-mediated
rejection, N (%)
4 (9.5)b 2 (1.3) 0.03
Grafts lost for interstitial ﬁbrosis and tubular atrophy, N
(%)
2 (4.7) 8 (5.4) 0.82
Grafts lost for other causes, N (%) 1(2.4) 8 (5.4) 0.68
Total grafts lost, N (%) 22 (52.3) 36(24.3) 0.0001
Infections, N (%) 20 (47.6) 71 (47.9) 0.89
Deaths, N (%) 4 (9.5) 10 (6.7) 0.78
tx, transplant; CAPD, continuous ambulatory peritoneal dialysis; HD, haemodialysis .
All the values are reported as median and interquartile ranges if not differently speciﬁed.
*P-value refers to the statistical signiﬁcance of the variables either in the Cox proportional hazard regression (for a continuous variable) or
in the log-rank test for survival curves difference (for a discrete or discretized variable).
aRecurrence was considered as a concomitant cause of graft loss in two cases of chronic/active T-cell-mediated rejection.
bRecurrence was considered as a concomitant cause of graft loss in all four cases of chronic active antibody-mediated rejection.
O
R
IG
IN
A
L
A
R
T
IC
L
E
G. Moroni et al.
1310
D
ow
nloaded from
 https://academ
ic.oup.com
/ndt/article-abstract/28/5/1305/1921459 by U
ni M
Ilano user on 05 O
ctober 2018
to be better than that of controls [3, 4, 5, 28], at 10 years the
graft survival of the two groups became similar [3, 6, 8] or was
even worse in IgAN patients [7, 5]. Choy et al. [7] reported
that the graft survival after 10 years was worse in IgAN
patients than in controls; in particular, the two survival curves
crossover at around 12 years. In our cohort, the death censored
graft survival in IgAN patients was worse than in controls
even considering death as a competing risk. Whilst at 5 years,
the graft survival of IgAN patients was slightly better than that
of controls, after 5 years the graft survival of IgAN patients
became progressively worse than that of controls. To strength-
en this result, we performed a multivariate Cox regression
analysis to predict graft loss pooling together IgAN patients
and controls. IgAN emerged as an independent predictor of
graft loss at multivariate analysis together with the occurrence
of acute rejection and delayed graft function recovery.
Recurrence of IgAN developed in 21.2% of our transplant
patients and in 35.5% of patients subjected to graft biopsy after
a median follow-up of 4 years after transplantation, ranging
from a few months to 15 years. In our centre, patients receive
graft biopsy only when they present with clinical manifes-
tations; thus, our rate of recurrence might be underestimated,
considering that histological recurrences have been demon-
strated in the absence of clinical symptoms [12, 29]. The
outcome of grafts with silent recurrent IgA deposits is contro-
versial: in some cases, the disease progressed to overt IgAN,
[15] and in others, IgA deposits disappeared in subsequent
biopsies [16]. These data underline that the course of the re-
currence of IgAN can be extremely variable. As a matter of
fact, in seven of our recurrent patients who presented with
microscopic haematuria and proteinuria, the urinary abnorm-
alities completely disappeared during the follow-up. In con-
trast, 12 grafts of our cohort were lost due to recurrence and in
6 other grafts, the recurrence was considered as a concomitant
F IGURE 1 : (A) Kaplan–Meier estimates of patient survival in
patients with IgAN (dashed line) and in controls (solid line). (B)
Kaplan–Meier estimates of death-censored graft survival in patients
with IgAN (dashed line) and in controls (solid line).
Table 3. Classiﬁcation of the histological lesions of recurrent grafts according to Oxford
classiﬁcation (25)
A functioning
grafts at last
follow-up:
(16a patients)
B grafts lost
for
recurrence:
(12 patients)
P (A versus B) C grafts lost for
recurrence + other
causes:
(6 patients)
D grafts not
lost for
recurrence:
(4 patients)
Mesangial
hypercellularity
>50% of glomeruli
3 10 0.003 3 1
Segmental
glomerulosclerosis
present
3 12 0.000 5 1
Endocapillary
hypercellularity
present
6 11 0.012 5 1
Tubular atrophy/
interstitial ﬁbrosis
>25% of specimen
0 6 0.036 2 3
aExcluded the four patients who died with a functioning graft.
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cause of graft failure. Thus, graft loss due to recurrence ac-
counted for 8.4% of our IgAN transplanted patients, compar-
able with the reported rate in the literature, which ranges from
1.3 to 16% [3, 4, 6, 7, 12–23]. In large cohorts of transplanted
recipients, the histological recurrence of any type of glomeru-
lonephritis emerged as a signiﬁcant cause of graft loss associ-
ated with a signiﬁcant reduction in graft survival [10, 11, 30].
For IgAN, not all authors were able to demonstrate a negative
impact of recurrence on graft survival [3, 21–24]. In our
cohort, recurrent patients tended to have a worse graft survival
than non-recurrent patients, in particular from 10 years after
renal transplantation, while graft survival of non-recurrent
patients was similar to that of controls. These data seem to
suggest that recurrence could be one of the factors responsible
for the worse graft survival of IgAN patients in comparison to
controls.
As suggested for IgAN in the native kidney [25], the
Oxford classiﬁcation applied to recurrent graft biopsies seems
to be able to identify patients with a worse graft outcome.
Another unsolved question is whether living donor
kidneys have a higher risk of recurrence and graft deterio-
ration than the kidneys from deceased donors. Some studies
have failed to detect a signiﬁcant difference [3, 6, 16, 21],
while others noted a negative impact of living donors on the
graft outcome [18–20, 23, 30]. In our cohort, patient and
graft survival of recipients from living-related donors were
not different from that of recipients from deceased donors
and no difference emerged in the rate of recurrence between
the two groups.
In the evaluation of the predictors of recurrence, we
found, in contrast to that reported in another paper [30],
that the transplant year was associated with the risk of recur-
rence: recurrence of IgAN signiﬁcantly reduced from 1981
to 2010 and in particular, recurrences occurred less fre-
quently in transplants performed during the decade 2000–
2010. There is no clear explanation for our results: one possi-
bility could be the new immunosuppressive approach em-
ployed in kidney transplantation in recent years. In actual
fact, in contrast to other papers [21, 23, 30], our results at
univariate analysis underline a possible role of maintenance
immunosuppressive therapy in reducing the risk of recur-
rence. Patients treated with mycophenolate and those who
received any type of triple immunosuppressive therapy had a
lower risk of recurrence. Among the other features evaluated
F IGURE 2 : Gantt chart reporting the outcome of IgAGN patients
with and without IgA recurrence. Numbers at the end of the bars
refer to the median follow-ups in months.
F IGURE 3 : (A) Kaplan–Meier estimates of death censored graft
survival in patients with recurrence of IgAN (dashed line) and in
those without recurrence (solid line). (B) Kaplan–Meier estimates of
death-censored graft survival in patients with IgAN who do not
develop recurrence (dashed line) and in controls (solid line).
F IGURE 4 : Kaplan–Meier estimates of the probability of recurrence
of IgAN in the decades 1981–1989 (number of patients 32, number of
recurrences 13), 1990–1999 (number of patients 96, number of recur-
rences 23), 2000–2010 (number of patients 74, number of recurrences
6).
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in univariate analysis, only the young age at renal transplan-
tation was associated with a higher risk of recurrence as de-
monstrated by others [6, 22, 23].
At multivariate analysis, the older age of patients and any
triple immunosuppressive therapy were independent protec-
tive factors against the recurrence of IgAN. However, multi-
variate Cox regression analysis could have been impaired by
the small number of patients showing recurrence (n = 42).
These data need to be conﬁrmed in larger prospective studies.
As reported by others [31, 32], we found that the presence
of crescents at graft biopsy in recurrent IgAN patients is
associated with a worse graft outcome.
No guidelines for the treatment of recurrence of IgAN in
renal transplant are currently available. Recently, Mulay et al.
[33] reported that, after adjusting for important covariates, the
use of cyclosporine, tacrolimus, azathioprine, mycophenolate
mofetil, sirolimus or prednisone was not associated with graft
failure due to recurrent glomerulonephritis, including IgAN,
while Clayton et al. [34] suggested that steroid withdrawal may
increase the graft loss risk because of recurrence of IgAN.
Notably, both of these two papers [33, 34] reported an appar-
ent reduction in graft loss from recurrence of IgAN in recent
years. The use of angiotensin-converting enzyme inhibitors
was not associated with an improvement of graft survival in
our recurrent patients, in contrast to what has been reported
in other studies [35].
The limitations of our study are obviously its retrospective
nature, the relatively low number of patients evaluated, the
non-uniformed immunosuppressive regimen due to the long
duration of the observation and the lack of control biopsies:
this does not allow us to draw ﬁrm conclusions about the pre-
dictors of recurrence. With these limitations, our results
suggest that in the long term death-censored graft survival of
IgAN transplant patients seems to be worse in comparison to
that of controls; this result is strengthened by the demon-
stration that IgAN emerged as an independent predictor of
graft loss. Recurrence seems to be one of the factors respon-
sible for the worse graft outcome of IgAN patients, as those
who did not develop recurrence had a graft survival not differ-
ent from that of controls.
The progressive reduction of recurrences suggested by our
data and the apparent reduction in graft loss from recurrent
IgAN reported by other authors [33, 34] in recent years may
portend a progressive improvement in the prognosis of renal
transplant in IgAN patients in the near future.
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